U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07240896) titled 'A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)' on Sept. 25.
Brief Summary: This study adopted an open, single-arm, non-randomized, dose-escalation research design, aiming to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetic and immunogenicity characteristics of single and multiple intravenous infusions of DSL101 in patients with Wilson's disease.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Wilsons Disease
Intervention:
DRUG: Group 1: DSL101 Low dose
Subjects will receive intravenous infusions of DSL101 once every four weeks.
DRUG: Group 2: DSL10...